Clinical Trials Browser

Lutetium-177 × NET × Clear all

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

Neuroendocrine Tumors

NCT05249114 2025-03-10

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Phase 1 Active not recruiting

Neuroendocrine Tumors

NCT04261855 2025-02-14

GoTHAM

Phase 1/2 Recruiting

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04949282 2022-12-23

SEPTRALU

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Stomach Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT04790708 2021-03-10

FENET-2016

Phase NA Unknown

Neuroendocrine Tumors

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Phase NA Completed

Neuroendocrine Tumors